| |
| Issue |
Title |
| |
| Vol 13, No 2 (2025) |
The Effect of Potentially Hepatotoxic Medicinal Products on Alanine Transaminase Levels in COVID-19 Patients: A Case–Control Study |
Abstract
PDF (Rus)
|
|
V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva |
| |
| Vol 13, No 2 (2025) |
Thrombocytopenia as a Side Effect of Heparin Therapy and COVID-19 Vaccination: A Review |
Abstract
PDF (Rus)
|
|
S. S. Postnikov, N. V. Teplova, O. V. Gulbekova |
| |
| Vol 13, No 2 (2025) |
Safety of Biological Medicinal Products for Hereditary Coagulopathies: An Analysis of the Russian Pharmacovigilance Database |
Abstract
PDF (Rus)
|
|
D. S. Fokina, O. V. Zhukova, A. L. Khokhlov |
| |
| Vol 13, No 2 (2025) |
Predicting the Relative Risk of Pharmacotherapy Based on a Mathematical Model of Age-Related Decline in Homeostasis in Elderly and Senile Patients |
Abstract
PDF (Rus)
|
|
R. D. Syubaev, G. N. Engalycheva |
| |
| Vol 13, No 2 (2025) |
Pharmacovigilance in the Geriatric Population: Analysis of Risk Management Plans for Medicinal Products in Russia in 2024 |
Abstract
PDF (Rus)
|
|
N. V. Tereshkina, N. Yu. Velts, E. O. Zhuravleva, G. V. Kutekhova, S. V. Glagolev, V. V. Kosenko |
| |
| Vol 13, No 2 (2025) |
Risk Assessment Algorithms in Pharmacovigilance: A Review |
Abstract
PDF (Rus)
|
|
T. M. Bukatina |
| |
| 1 - 6 of 6 Items |
|
